Udvalget bemærkede, at anvendelse af Diovan efter MI i nogle medlemsstater var begrænset til patienter, der er intolerante over for ACE- hæmmere.
The Committee noted that some Member States (MSs) had a limitation of the use of Diovan after MI to patients intolerant to ACE inhibitors.